{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T02:16:33Z","timestamp":1776824193244,"version":"3.51.2"},"reference-count":22,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2016,11,17]],"date-time":"2016-11-17T00:00:00Z","timestamp":1479340800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Astellas Pharma Inc"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["LUTS"],"published-print":{"date-parts":[[2018,5]]},"abstract":"<jats:sec><jats:title>Objectives<\/jats:title><jats:p>To provide real\u2010world data on<jats:styled-content style=\"fixed-case\">J<\/jats:styled-content>apanese patients with overactive bladder (<jats:styled-content style=\"fixed-case\">OAB<\/jats:styled-content>) initiating treatment with the \u03b2<jats:sub>3<\/jats:sub>\u2010adrenoceptor agonist, mirabegron. This study examined prescribing patterns, adverse drug reaction (<jats:styled-content style=\"fixed-case\">ADR<\/jats:styled-content>) incidence, and treatment effectiveness.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Full medical histories, including prior\/concomitant drug use, were collected before initiating mirabegron treatment. After 12\u2009weeks mirabegron, physicians assessed<jats:styled-content style=\"fixed-case\">ADR<\/jats:styled-content>incidence and treatment effectiveness. Residual urine volume was assessed and patients completed the<jats:styled-content style=\"fixed-case\">O<\/jats:styled-content>veractive<jats:styled-content style=\"fixed-case\">B<\/jats:styled-content>ladder<jats:styled-content style=\"fixed-case\">S<\/jats:styled-content>ymptom<jats:styled-content style=\"fixed-case\">S<\/jats:styled-content>core (<jats:styled-content style=\"fixed-case\">OABSS<\/jats:styled-content>) and<jats:styled-content style=\"fixed-case\">I<\/jats:styled-content>nternational<jats:styled-content style=\"fixed-case\">P<\/jats:styled-content>rostate<jats:styled-content style=\"fixed-case\">S<\/jats:styled-content>ymptom<jats:styled-content style=\"fixed-case\">S<\/jats:styled-content>core\u2010<jats:styled-content style=\"fixed-case\">Q<\/jats:styled-content>uality of<jats:styled-content style=\"fixed-case\">L<\/jats:styled-content>ife (<jats:styled-content style=\"fixed-case\">I\u2010PSS QoL<\/jats:styled-content>) surveys at<jats:styled-content style=\"fixed-case\">B<\/jats:styled-content>aseline and 12\u2009weeks. Data were collected between<jats:styled-content style=\"fixed-case\">A<\/jats:styled-content>pril 2012 and<jats:styled-content style=\"fixed-case\">J<\/jats:styled-content>uly 2014.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Of 9795<jats:styled-content style=\"fixed-case\">OAB<\/jats:styled-content>patients (46.8% male; 80.8% \u226565\u2009years), 71.7% had coexisting disease [notably benign prostatic hyperplasia (<jats:styled-content style=\"fixed-case\">BPH<\/jats:styled-content>, 32.4%), hypertension (31.9%), and diabetes mellitus (9.4%)] and 53.4% reported concomitant drug use (27.8% \u03b1<jats:sub>1<\/jats:sub>\u2010antagonists, 6.3% anticholinergics). The incidence of total<jats:styled-content style=\"fixed-case\">ADRs<\/jats:styled-content>was 6.07% [including constipation (0.97%), thirst (0.47%), and dysuria (0.44%)], of serious<jats:styled-content style=\"fixed-case\">ADRs<\/jats:styled-content>, 0.21%, of cardiovascular<jats:styled-content style=\"fixed-case\">ADRs<\/jats:styled-content>, 0.48% and of urinary retention, 0.31%. Incidence of total<jats:styled-content style=\"fixed-case\">ADRs<\/jats:styled-content>in patients with concomitant cardiovascular disease was 10.09% and of those related to urinary retention in men with untreated<jats:styled-content style=\"fixed-case\">BPH<\/jats:styled-content>, 0.88%. After 12\u2009weeks treatment, physicians judged mirabegron as \u201ceffective\u201d in 80.7% of patients, 63.6% of patients achieved the three\u2010point minimal clinically important change from<jats:styled-content style=\"fixed-case\">B<\/jats:styled-content>aseline in the mean<jats:styled-content style=\"fixed-case\">OABSS<\/jats:styled-content>, and the<jats:styled-content style=\"fixed-case\">I\u2010PSS QoL<\/jats:styled-content>decreased significantly from<jats:styled-content style=\"fixed-case\">B<\/jats:styled-content>aseline (\u22122.1\u2009\u00b1\u20091.77;<jats:italic><jats:styled-content style=\"fixed-case\">P<\/jats:styled-content><\/jats:italic>\u2009&lt;\u20090.001).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>In the clinical setting, mirabegron is well tolerated, with no unanticipated<jats:styled-content style=\"fixed-case\">ADRs<\/jats:styled-content>, and is an effective treatment for<jats:styled-content style=\"fixed-case\">J<\/jats:styled-content>apanese patients with<jats:styled-content style=\"fixed-case\">OAB<\/jats:styled-content>.<\/jats:p><\/jats:sec>","DOI":"10.1111\/luts.12148","type":"journal-article","created":{"date-parts":[[2016,11,17]],"date-time":"2016-11-17T09:50:50Z","timestamp":1479376250000},"page":"122-130","source":"Crossref","is-referenced-by-count":27,"title":["Safety and Effectiveness of Mirabegron in Patients with Overactive Bladder in a Real\u2010World Clinical Setting: A<scp>J<\/scp>apanese Post\u2010Marketing Study"],"prefix":"10.1111","volume":"10","author":[{"given":"Yumiko","family":"NOZAWA","sequence":"first","affiliation":[{"name":"Medical Science, Medical Affairs, Astellas Pharma Inc. Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daisuke","family":"KATO","sequence":"additional","affiliation":[{"name":"Medical Science, Medical Affairs, Astellas Pharma Inc. Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiromi","family":"TABUCHI","sequence":"additional","affiliation":[{"name":"Medical Research, Medical Affairs, Astellas Pharma Inc. Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kentarou","family":"KUROISHI","sequence":"additional","affiliation":[{"name":"Japan\u2010Asia Data Science, Development, Astellas Pharma Inc. Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2016,11,17]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-4295(02)02243-4"},{"key":"e_1_2_7_3_1","first-page":"6","article-title":"Maximizing the treatment of overactive bladder in the elderly","volume":"10","author":"Macdiarmid SA","year":"2008","journal-title":"Rev Urol"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2008.07601.x"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2010.09993.x"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2005.05835.x"},{"key":"e_1_2_7_7_1","first-page":"S121","article-title":"Persistence with overactive bladder pharmacotherapy in a Medicaid population","volume":"11","author":"Shaya FT","year":"2005","journal-title":"Am J Manag Care"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.108.142562"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/nau.22505"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2005.01.006"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2015.01.087"},{"key":"e_1_2_7_12_1","unstructured":"Pharmaceutical Administration and Regulations in Japan.Japanese Pharmaceutical Manufacturers Association. [Cited 25 Jan 2016.]2015. Available from URL:http:\/\/www.jpma.or.jp\/english\/parj\/pdf\/2015.pdf."},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1442-2042.2011.02860.x"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/bju.12649"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/luts.12053"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/luts.12107"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2013.05.062"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/luts.12091"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2014.09.091"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1987.03390220074024"},{"key":"e_1_2_7_21_1","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/S0031-6997(24)01425-X","article-title":"Adrenergic and muscarinic receptors in the human heart","volume":"51","author":"Brodde OE","year":"1999","journal-title":"Pharmacol Rev"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2015.09.007"},{"key":"e_1_2_7_23_1","unstructured":"United Nations Department of Economic and Social Affairs Population Division 2015"}],"container-title":["LUTS: Lower Urinary Tract Symptoms"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fluts.12148","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fluts.12148","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/luts.12148","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T18:04:56Z","timestamp":1749751496000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/luts.12148"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11,17]]},"references-count":22,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,5]]}},"alternative-id":["10.1111\/luts.12148"],"URL":"https:\/\/doi.org\/10.1111\/luts.12148","archive":["Portico"],"relation":{},"ISSN":["1757-5664","1757-5672"],"issn-type":[{"value":"1757-5664","type":"print"},{"value":"1757-5672","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,11,17]]}}}